Enlivex is a clinical-stage biotechnology company focused on macrophage reprogramming that intends to develop and commercialize a drug pipeline for macrophage reprogramming in solid cancers, sepsis and other indications.

The company’s pioneering cell-based therapy Allocetra™ breaks with old paradigms, offering to effectively treat numerous acute conditions through a radically different clinical approach that centers around macrophage homeostasis.